![[Important Notice] Porton Announcement Regarding The Change Of Email Domain](/Data/File/@W700/427-01.jpg "[Important Notice] Porton Announcement Regarding The Change Of Email Domain")
Your current status
- Necessary
- Analytics
- Targeting
Show details
DELI
03.07.2025
Porton Awarded Gold Medal by EcoVadis, Ranked Among the Top 5% Globally
Chongqing, China, June 13, 2025 - Porton Pharma Solutions Ltd. (Porton) today announced that its Changshou site, a flagship site for small molecule API manufacturing, has been awarded a gold medal in the latest EcoVadis sustainability rating, ranking in the top 5% of all participating companies. This achievement not only represents a strong endorsement of Porton’s long-term practices in sustainable development, but also highlights its responsibility in the global pharmaceutical industry chain.
DELI
Porton Announces 2030 Sustainability Targets on World Environment Day
Porton Awarded Gold Medal by EcoVadis, Ranked Among the Top 5% Globally
Porton Pharma Solutions Celebrates 20 Years of Excellence and Innovation
Porton to Showcase Integrated CDMO Expertise at BOS Basel 2025
Join Us at Chemspec Europe 2025 in June
Porton's Near-Term Target Validated by the SBTi
Porton Wins Outsourced Pharma 2025 CDMO Leadership Award
Porton to Showcase Cutting-edge Innovations at BIO-Europe Spring 2025
Join Porton at Leading Industry Conferences to Explore Innovations and Network with Experts
Porton Has Been Invited to the China–Slovenia Business and Investment Forum and Had a Friendly Meeting with Slovenian Officials.
Porton’s New Modality Capacity Upgrade Ceremony Successfully Held
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
Driving innovation and excellence in the CDMO industry, Porton Pharma Solutions 2024 CPHI Europe Review
Technical Enability | Porton’s Team of Global Chemical Engineering and Technology Published Breakthrough Results in Crystal Growth & Design and reported them at the 2024 Crystal Engineering Gordon Research Conference
Keep hope alive! We invite you to stay tuned to DMD
Porton Experts Invited To Participate In The University Of Perugia Master PRO-API Program, Aiding In The Training Of Green Process Chemistry Professionals
Porton Will Be Participating In Biotech Outsourcing Strategies Events This June
Proton At CPhI North America Again
Porton 2023 ESG Report
Upcoming Porton Shows In Europe And The USA：Shaping Our Future Together
Porton Makes Debut At DCAT Week 2024 To Jointly Promote Industry Development
Join Our Founder And CEO @ DCAT Week
Porton Pharma Solutions Joined The SBTi To Drive Climate Action
Farewell To 2023, And WE Are Sailing Forward To 2024
The Pharma Crystallization Summit (PCS) Is Held Annually To Bring Together Developers Of New Medicines With Crystallization Challenges And The Crystallization Experts (Solution Providers) In The Industry And Academia.
Porton Gets Improved In The 2023 S&P Global ESG Score
Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services
Pharma Digital Intelligence Summit Will Be Held On 5th, September, 2023
[Important Notice] Porton Announcement Regarding The Change Of Email Domain
Porton Unveils Its Small Molecule Platform Headquarters In Shanghai
PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai
Porton At DCAT Week 2023: A Highly Successful And Strategic Event
Porton Released 2022 CSR Report
Porton Delivers Strong 2022 Performance With 127% Sales Growth
Porton Gets Above-Average S&P Global Environmental, Social, And Governance (ESG) Score